Concord Drugs logo

Concord Drugs

CONCORDDRUGSLTD NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹105 Cr
Volatility
Moderate
P/E Ratio
51.9
EBITDA
₹4.52 Cr
Return on Equity
0.99%
Debt to Equity
0.24
Book Value
₹36.82
EPS
₹0.01
52W High
₹92.52
52W Low
₹61

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is expected to give good quarter

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -9.31%
  • The company has delivered a poor sales growth of 8.13% over past five years.
  • Company has a low return on equity of 1.63% over last 3 years.

Growth Rate

Revenue Growth
73.82% higher than 3Y
Net Income Growth
250% higher than 3Y
Cash Flow Change
371% higher than 3Y
ROE
-29.29% lower than 3Y
ROCE
5.76% higher than 3Y
EBITDA Margin (Avg.)
-37.4% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
8.79
7.38
12.62
14.47
6.35
11.84
10.77
7.96
13.38
10.07
16.84
35.56
20.9
Expenses
7.39
5.85
12.06
14.28
5.62
11.05
9.45
7.03
12.44
9.06
15.96
34.13
18.66
Operating Profit
1.4
1.53
0.56
0.19
0.73
0.79
1.32
0.93
0.94
1.01
0.88
1.43
2.24
OPM %
15.93%
20.73%
4.44%
1.31%
11.5%
6.67%
12.26%
11.68%
7.03%
10.03%
5.23%
4.02%
10.72%
Other Income
0
0.01
0
0
0
0.01
0
0
0
0
0.02
0
0
Interest
0.39
0.39
0.43
0.38
0.37
0.39
0.43
0.53
0.42
0.4
0.3
0.34
0.35
Depreciation
0.38
0.38
0.38
0.39
0.34
0.34
0.37
0.37
0.37
0.34
0.3
0.35
0.35
PBT
0.63
0.77
-0.25
-0.58
0.02
0.07
0.52
0.03
0.15
0.27
0.3
0.74
1.54
Tax %
23.81%
31.17%
-4%
-39.66%
50%
28.57%
57.69%
33.33%
26.67%
29.63%
26.67%
28.38%
27.92%
Net Profit
0.49
0.53
-0.24
-0.35
0.01
0.05
0.22
0.01
0.11
0.19
0.22
0.52
1.11
EPS in Rs
0.53
0.57
-0.24
-0.35
0.01
0.05
0.22
0.01
0.11
0.19
0.17
0.39
0.84
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
40.02
50.68
57.43
51.8
48.08
51.34
51.33
58.96
51.31
43.26
36.93
75.88
83.37
Expenses
32.99
42.38
51.93
47.02
44.43
48
48.11
53.37
46.97
39.58
33.16
71.61
77.81
Operating Profit
7.03
8.3
5.5
4.78
3.65
3.34
3.22
5.59
4.34
3.68
3.77
4.27
5.56
OPM %
17.57%
16.38%
9.58%
9.23%
7.59%
6.51%
6.27%
9.48%
8.46%
8.51%
10.21%
5.63%
6.67%
Other Income
0.37
0.15
0.09
0.14
0.09
0.12
3.86
0.1
0.01
0.01
0.01
0
0.02
Interest
2.72
2.57
2.36
1.88
1.59
1.54
1.42
1.68
1.62
1.59
1.72
1.46
1.39
Depreciation
3.63
2.91
2.58
2.4
1.71
1.46
1.37
1.76
1.6
1.54
1.42
1.36
1.34
PBT
1.05
2.97
0.65
0.64
0.44
0.46
4.29
2.25
1.13
0.56
0.64
1.45
2.85
Tax %
33.33%
40.74%
73.85%
50%
9.09%
28.26%
23.54%
28.89%
21.24%
25%
54.69%
28.28%
—
Net Profit
0.7
1.75
0.16
0.32
0.41
0.33
3.28
1.59
0.89
0.42
0.3
1.04
2.04
EPS in Rs
0.97
2.42
0.22
0.41
0.52
0.38
3.75
1.82
0.96
0.42
0.3
0.79
1.59
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7.24
7.24
7.24
7.86
7.86
8.74
8.74
8.74
9.32
10
10
13.18
Reserves
6.07
7.82
11.75
11.46
15.29
14.74
18.02
19.62
22.38
23.82
24.11
35.34
Borrowings
21.27
19.99
15.43
13.62
9.83
9.57
12.97
16.43
15.63
14.93
16.91
11.61
Other Liabilities
19.63
17.44
21.11
73.48
49.79
24.96
10.15
11.66
9.31
7.55
7.56
11.72
Total Liabilities
54.21
52.49
55.53
106
82.77
58.01
49.88
56.45
56.64
56.3
58.58
71.85
Fixed Assets
18.32
15.18
13.64
13.51
11.85
10.52
13.83
13.97
12.86
11.63
12.17
11.55
CWIP
0
0
0
0
0.29
1
0
0.55
0.92
1.63
2
2.43
Investments
0
0
0
0
0
0
0
0
1.42
1.62
1.62
1.62
Other Assets
35.89
37.31
41.89
92.91
70.63
46.49
36.05
41.93
41.44
41.42
42.79
56.25
Total Assets
54.21
52.49
55.53
106
82.77
58.01
49.88
56.45
56.64
56.3
58.58
71.85
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1.75
3.05
1.7
6.88
1.19
2.48
1.62
0.77
2.24
1.96
3.16
-7.37
Investing
-1.1
0.23
-1.04
-2.21
-0.34
-0.84
-3.67
-2.44
-2.27
-1.21
-2.32
-1.13
Financing
-0.7
-3.42
-3.94
-4.8
-0.73
-1.79
2.07
1.68
0.05
-0.69
-0.87
8.65
Net Cash Flow
-0.06
-0.14
-3.28
-0.13
0.12
-0.15
0.02
0.01
0.03
0.06
-0.02
0.16
Free Cash Flow
0.65
3.28
0.66
4.6
0.85
1.63
-2.05
-1.69
1.38
0.94
0.83
-8.54
CFO/OP
33
51
38
152
36
78
65
26
60
59
89
-163
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
250
184
99.46
501
368
181
147
142
116
118
125
135
Inventory Days
65.82
76.39
87.31
157
172
141
101
152
156
203
253
103
Days Payable
208
92.05
130
559
393
110
26.76
62.25
45.98
35.17
45.03
33.73
Cash Conversion Cycle
108
168
57.27
98.98
146
212
221
231
227
285
333
204
Working Capital Days
68.04
113
4
79.27
102
103
140
112
145
127
134
148
ROCE %
11.35%
16.06%
8.67%
7.48%
6.16%
6.06%
5.36%
9.3%
5.97%
4.48%
4.73%
5.24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Concord Drugs insights

60 extracted metrics + investor summaries across FY12–FY26.

Log in — free

Shareholding Pattern

Public54.19%Others0.73%Promot.45.08%As ofJun 2026

Documents

Frequently Asked Questions about Concord Drugs

What does Concord Drugs Ltd do?
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations
Where is Concord Drugs Ltd (538965) listed?
Concord Drugs Ltd trades as CONCORDDRUGSLTD on the NSE and under code 538965 on the BSE.
Which sector does Concord Drugs Ltd belong to?
Concord Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Concord Drugs Ltd?
Concord Drugs Ltd has a market capitalisation of ₹105.41 Cr, which places it in the Small Cap band.
What is the PE ratio of Concord Drugs Ltd?
Concord Drugs Ltd trades at a PE ratio of 51.90, on earnings per share of ₹0.01, against a book value of ₹36.82 per share.
What is the 52-week high and low of Concord Drugs Ltd?
Over the last 52 weeks Concord Drugs Ltd has traded between ₹61 and ₹92.52.
What is the Return on Equity (ROE) of Concord Drugs Ltd?
Concord Drugs Ltd reported a return on equity of 0.99%. Its debt-to-equity ratio is 0.24.

Company Information

Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations

Website concorddrugs.in
Listed 2015-02-23
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/538965.md for Concord Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List